Consultant Oncoplastic Breast Surgeon | Clinical Lead @MidYorkshireNHS | @spirehealthcare Spire Leeds, Spire Methley Park | Breast surgeon Leeds Wakefield
Leeds, England
Joined May 2015
- Tweets437
- Following1.1K
- Followers747
- Likes6.5K
Daniel Glassman retweeted
📌 Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy
🔗 thelancet.com/journals/lance…
👉🏻 Allocation to 5 further years of AIT reduced subsequent distant recurrence rates by about a quarter
👉🏻 The absolute further recurrence reduction from 5 further years of AIT appeared greater for women with node-positive than node-negative disease
👉🏻 1·2% excess 5-year incidence of reported bone fracture
@OncoAlert #OncoAlertAF @TheLancetOncol
Daniel Glassman retweeted
New guidance on pregnancy and breast cancer is available on the ABS Information Hub. This evidence-based guidance provides recommendations to support the treatment of patients with pregnancy associated breast cancer. Access the guidance here: buff.ly/eIHqbNx
Daniel Glassman retweeted
The ABS has published guidance on the management of phyllodes tumours of the breast, which provides easily accessible evidence and recommendations for all clinicians managing patients with phyllodes tumours. Find out more: associationofbreastsurgery.o…
Daniel Glassman retweeted
Important!
ASTER 70s trial in women ≥70y with ER+, HER2– breast cancer deemed high-risk by genomic signature (GGI) showed no OS benefit from adding chemo to hormonotherapy.
8y OS: 72.7% vs 68.3% (HR 0.83; p=0.21)
Toxicity: G3+ AEs 34% vs 9%
👉 More toxicity, no survival gain!
#BreastCancer #Oncology #ClinicalTrials #GeriatricOncology @oncoalert
@TheLancet @Larvol @onder_haka2124
Daniel Glassman retweeted
💊Adjuvant endocrine therapy in pre and post menopausal patients with HR(+) breast cancer 👇
@OncoAlert @Lucarecco @ElisaAgostinett #cancer #breast #oncology #MedX
More fantastic reviews by my patients.
I see patients with breast symptoms at Spire Methley Park Hospital every Wednesday afternoon. One-stop assessment including consultation, mammograms, ultrasound scans and if needed biopsies all in the same visit.
spirehealthcare.com/consulta…
Daniel Glassman retweeted
📣 New ABS Guidance available 📣
Led by the ABS, a multi-disciplinary writing group has produced new guidance providing #ClinicalTeams with evidence-based recommendations for the management of radial surgical margins after BCS for DCIS. Read here: buff.ly/3BUR9LP
Daniel Glassman retweeted
Check out Dr. Paolo Tarantino @PTarantinoMD @DFCI_BreastOnc discussing #ASCO24 Breast Cancer highlights focused on top abstracts and clinical practice implications
Full📽️on #VuMedi
👇
shorturl.at/Zc79i
#bcsm #breastcancer #BestofASCO24
Lots of new studies in recent years that have improved breast cancer treatment
Daniel Glassman retweeted
Overall survival after mastectomy versus breast-conserving surgery with adjuvant radiotherapy for early-stage breast cancer: meta-analysis
➡️doi.org/10.1093/bjsopen/zrae…
This systematic review and meta-analysis of 35 recent observational studies published between 1 January 2000 and 18 December 2023 including 909 077 patients demonstrated a survival advantage for women undergoing breast-conserving surgery with adjuvant radiotherapy for early-stage breast cancer compared with mastectomy. The pooled HR was 0.72 (95% c.i. 0.68 to 0.75, P < 0.001). Although these results should be interpreted with caution due to the low certainty of evidence, they should be shared with patients to support informed surgical decision-making.
👏👏👏@kirankrajan, Katherine Fairhurst, Beth Birkbeck, Shonnelly Novintan, Rebecca Wilson, Jelena Savović, Chris Holcombe, Shelley Potter
#SoMe4Surgery #MedTwitter #SurgEd #Surgery @me4_so @for_surgery @for_surgeons @modern_surgeon @surggpt @BJSAcademy @BJSurgery @young_bjs @juliomayol @JJEarnshaw @OUPMedicine #breastcancer #mastectomy #endocrine
Daniel Glassman retweeted
The CDK4/6i abemaciclib has regulatory approval in the metastatic & early settings of HR+/HER2- breast cancer (BC):
🔹Metastatic BC: with an AI as 1st line therapy and with fulvestrant after an AI
🔹Early BC: with endocrine therapy for patients with high risk of recurrence.
Daniel Glassman retweeted
NEWS FROM INDUSTRY
Results from the DESTINY-Breast06 trial indicate that trastuzumab deruxtecan🧪could become a new standard of care for #HER2 -low 🧬and HER2-ultralow metastatic #BreastCancer patients
➡️showing significant PFS improvements 📈over standard chemotherapy after prior endocrine therapy
Source
astrazeneca.com/media-centre…
Pinging @OncoAlert 🚨 #BreastCancer Faculty
Breast
@matteolambe @aftimosp @E_de_Azambuja @NicoleKuderer @FAndreMD @prat_aleix @DrSGraff @jesusanampa @StoverLab @curijoey @ErikaHamilton9 @double_whammied @stage4kelly @coffeemommy @itsnot_pink @maryam_lustberg @IBCResearch @kevinpunie @nicolobattisti @raalbany @hoperugo @teamoncology @stolaney1
@LoiSher @SirohiBhawna @chemobrainfog @jamecancerdoc @DrRBarroso @JavierCortesMD @JaniceTNBCmets @paspears88 @MammaMiaMagazin @itrisabel
#OncoAlertAF
@nataliagandur @acampsmalea @MartaPerachino @heinrich_kat @BiagioRicciutMD @DenizCanGuven1
@yekeduz_emre @HHorinouchi @FadiHaddad_MD
@Dr_Ivanoncologo @Abdallah81MD @FernandoOnco
@ElisaAgostinett @dr_yakupergun @to_be_elizabeth
